Novel glutamatergic drugs for the treatment of mood disorders
Kyle AB Lapidus, Laili Soleimani, James W MurroughMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USAAbstract: Mood disorders are common and debilitating, resulting in a significant public health burden. Current treatments are only...
Guardado en:
Autores principales: | Murrough JW, Lapidus KAB, Soleimani L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c642c0191b914f869c9fb57dce8d4303 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of nucleus accumbens glutamatergic plasticity in drug addiction
por: Quintero GC
Publicado: (2013) -
Cerebellar dysregulation and heterogeneity of mood disorders
por: Tobe EH
Publicado: (2014) -
Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment
por: Gérard A, et al.
Publicado: (2012) -
Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study
por: Luca M, et al.
Publicado: (2013) -
Mood disorders and complementary and alternative medicine: a literature review
por: Qureshi NA, et al.
Publicado: (2013)